Latest Ranibizumab Stories
With Americans spending billions of dollars each year on nutritional supplements, researchers have analyzed popular eye vitamins to determine whether their formulations and claims are consistent with scientific findings.
Research shows that, of 11 popular supplements analyzed, 7 do not adhere to proven formulas; all 11 have misleading claims SAN FRANCISCO, Dec.
Conference Call Scheduled for Wednesday, December 3rd to Provide Investor Update SAN DIEGO, Dec. 2, 2014 /PRNewswire/ -- Lpath, Inc.
CRESTWOOD, Ky., Nov. 20, 2014 /PRNewswire/ -- Apellis Pharmaceuticals announced today that it entered into an agreement to acquire Potentia Pharmaceuticals.
Novel Therapies Demonstrating Evidence of Superior Head-to-Head Efficacy Will Expand the Role of Adjunct Therapy, According to Findings from Decision Resources Group BURLINGTON, Mass., Nov.
Desire for Greater Efficacy and Improved Convenience Drive Perceived Value of Emerging Therapies for Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON,
Ophthotech/Novartis's Fovista Will Exceed $500 Million in 2023 Sales as a Treatment for the Wet Form of the Disease, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.
TARRYTOWN, N.Y., Oct. 17, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc.
-- Fourth indication for injection treatment that can stabilize and improve vision(1) -- mCNV a leading cause of visual impairment among those 20-50 years of age(9) Since
Fovista and Abicipar Pegol Will Need to be Priced Competitively to Current Agents to Garner Favorable Tier Placement, According to Findings from Decision Resources Group BURLINGTON, Mass.,
- A trick or prank.